AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
Crossref DOI link: https://doi.org/10.1186/1756-9966-33-47
Published Online: 2014-05-30
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mu, Zhaomei
Klinowska, Teresa
Dong, Xiaoshen
Foster, Emily
Womack, Chris
Fernandez, Sandra V
Cristofanilli, Massimo
Article History
Received: 4 February 2014
Accepted: 13 May 2014
First Online: 30 May 2014